吉西他滨联合化疗方案治疗晚期胆系肿瘤44例临床分析  

Combined chemotherapy of Gemcitabine in advanced biliary cancer:report of 44 cases

作　　者：陈坚[1] 魏燕[1] 邱书珺[1] 吴俊兰[1] 高巍然[1] 孔祥军[1] 瞿琴[1] 

机构地区：[1]中国人民武装警察部队上海市总队医院肿瘤科,上海201103

出　　处：《现代肿瘤医学》2015年第6期822-824,共3页Journal of Modern Oncology

摘　　要：目的:观察吉西他滨联合奥沙利铂与联合卡培他滨在晚期胆系肿瘤治疗中的疗效。方法:回顾性分析44例接受以吉西他滨为基础联合化疗的晚期胆系肿瘤病例,其中接受与奥沙利铂联合化疗的19例,接受与卡培他滨联合化疗的25例,比较两组患者的疗效及不良反应。结果:奥沙利铂组和卡培他滨组治疗有效率(RR)分别为31.6%(6/19)、28.0%(7/25),中位无疾病进展时间分别为6.4、7.0个月,中位生存期分别为15.4、14.0个月,均无统计学差异(P>0.05)。在不良反应方面,奥沙利铂组出现周围神经炎较多(4/19),卡培他滨组出现手足综合症较多(5/25),两组的肝脏功能损害、肾脏功能损害、骨髓抑制等不良反应无统计学差异。结论:吉西他滨为基础联合奥沙利铂或卡培他滨治疗晚期胆系肿瘤,不良反应相似,疗效无明显差异,均可做为治疗选择方案。Objective：Observe the effect of Gemcitabine combined with Oxaliplatin or combined with Capecitabine in the treatment of advanced gallbladder cancer.Methods： Retrospectively analyze 44 patients received Gemcitabine based on combination chemotherapy in advanced biliary cancer cases,which received Oxaliplatin combined chemotherapy in 19 cases,received Capecitabine combined chemotherapy in 25 cases,efficacy and adverse reactions was compared in two groups of patients.Results：Response rate（ RR） in the treatment of the two groups were respectively31.6%（6 /19）,28.0%（7 /25）.Progress free survival time of the two groups respectively 6.4 months,7.0 months.Median overall surviva1 time of the two groups respectively 15.4 months,14.0 months.There were no statistically sig nificant differences.In terms of adverse reactions,Oxaliplatin group appeared more surrounding neuritis,Capecitabine groups more hand-foot syndrome.There was no statistically significant difference in occurrence of impaired liver function,impaired renal function,bone marrow depression and other adverse reactions within two groups.Conclusion：Gemcitabine combined with Oxaliplatin or combined with Capecitabine in the treatment of advanced gallbladder cancer,have similar side effects,and no significant differences in efficacy.Both of them can be used as treatment options.

关 键 词：胆系肿瘤 吉西他滨 奥沙利铂 卡培他滨 化学治疗 

分 类 号：R735.8[医药卫生—肿瘤]